Inhibrx Biosciences (NASDAQ:INBX) CEO Mark Lappe Buys 4,500 Shares of Stock

Key Points

• CEO Mark Lappe purchased 4,500 Inhibrx Biosciences shares at an average price of $100.76, investing $453,420 and increasing his ownership by 0.61% to 740,548 shares. He has also made two other sizable purchases recently.
• INBX shares rose 2.1% to $101.71, giving the company a market capitalization of approximately $1.5 billion. The company recently reported a quarterly loss of $2.34 per share, slightly worse than analysts expected.
• Analyst sentiment is mixed, with ratings ranging from strong sell to strong buy, though the stock carries a “Moderate Buy” consensus and an average price target of $197.50. Institutional investors own 82.46% of the company.

Inhibrx Biosciences, Inc. (NASDAQ:INBX - Get Free Report) CEO Mark Lappe acquired 4,500 shares of the company's stock in a transaction dated Monday, September 28th. The shares were purchased at an average price of $100.76 per share, with a total value of $453,420.00. Following the completion of the acquisition, the chief executive officer owned 740,548 shares in the company, valued at approximately $74,617,616.48. The trade was a 0.61% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Mark Lappe also recently made the following trade(s):

• On Friday, September 25th, Mark Lappe bought 5,500 shares of Inhibrx Biosciences stock. The stock was purchased at an average price of $99.16 per share, for a total transaction of $545,380.00.
• On Tuesday, September 8th, Mark Lappe bought 25,000 shares of Inhibrx Biosciences stock. The stock was purchased at an average price of $105.82 per share, for a total transaction of $2,645,500.00.

Inhibrx Biosciences Trading Up 2.1%

INBX stock traded up $2.10 during trading on Monday, reaching $101.71. 187,060 shares of the stock traded hands, compared to its average volume of 319,038. The firm has a market capitalization of $1.50 billion, a PE ratio of -11.45 and a beta of 3.66. The company has a debt-to-equity ratio of 12.58, a current ratio of 5.07 and a quick ratio of 5.07. The business's 50 day moving average price is $101.24 and its 200-day moving average price is $95.58. Inhibrx Biosciences, Inc. has a 52-week low of $28.16 and a 52-week high of $155.29.

Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($2.34) EPS for the quarter, missing analysts' consensus estimates of ($2.28) by ($0.06). As a group, sell-side analysts forecast that Inhibrx Biosciences, Inc. will post -9.91 earnings per share for the current year.

Institutional Trading of Inhibrx Biosciences

Several large investors have recently bought and sold shares of the company. Opaleye Management Inc. purchased a new stake in shares of Inhibrx Biosciences during the second quarter valued at approximately $1,923,000. Tidal Investments LLC acquired a new stake in Inhibrx Biosciences during the 2nd quarter valued at $964,000. Integrated Wealth Concepts LLC acquired a new stake in Inhibrx Biosciences during the 2nd quarter valued at $31,000. NINE MASTS CAPITAL Ltd acquired a new stake in Inhibrx Biosciences during the 2nd quarter valued at $284,000. Finally, Harvest Management LLC purchased a new stake in Inhibrx Biosciences during the 2nd quarter worth $246,000. Institutional investors and hedge funds own 82.46% of the company's stock.

Analysts Set New Price Targets

INBX has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Inhibrx Biosciences in a research report on Friday, September 11th. Wall Street Zen lowered shares of Inhibrx Biosciences from a "hold" rating to a "strong sell" rating in a research report on Monday, August 17th. HC Wainwright started coverage on shares of Inhibrx Biosciences in a research note on Monday, August 24th. They issued a "buy" rating and a $245.00 target price on the stock. Finally, Citigroup restated a "market perform" rating on shares of Inhibrx Biosciences in a report on Friday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $197.50.

About Inhibrx Biosciences

Inhibrx Biosciences, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing biologic medicines for serious diseases with limited treatment options. The company uses a proprietary protein-engineering platform to design novel therapeutic proteins, including multivalent and long-acting biologics intended to selectively affect disease-related biological pathways.

Inhibrx's development programs have included INBRX-101, also known as efzofitimod, an engineered fibroblast growth factor 1 intended for the treatment of alpha-1 antitrypsin deficiency-associated emphysema and other inflammatory lung conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.